Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Platelet function testing: Current practice among clinical centres in Northern Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Factor levels in carriers of haemophilia are associated with familial severity: a Danish single centre study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Copenhagen founder variant GP1BA c.58T>G is the most frequent cause of inherited thrombocytopenia in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Arvelige trombocytsygdomme

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Nordic Haemophilia Council
Vis graf over relationer

INTRODUCTION: Platelet function tests are used to screen and diagnose patients with possible inherited platelet function defects (IPFD). Some acquired platelet dysfunction may be caused by certain drugs or comorbidities, which need to be excluded before testing.

AIMS: To identify current practice among centres performing platelet function tests in Northern Europe.

METHODS: A total of 14 clinical centres from Sweden (six), Finland (two), Denmark (two), Norway (one), Estonia (two) and Iceland (one) completed the survey questionnaire, the population capture area of about 29.5 million.

RESULTS: Six of the 14 (42.8%) centres providing platelet function assessment represent comprehensive treatment centres (EUHANET status). A Bleeding score (BS) or ISTH bleeding assessment tool (ISTH BAT score) is evaluated in 11/14 (78.6%) centres and family history in all. Five/14 centres (35.7%) use structured preanalytical patient instructions, and 10/14 (71.4%) recorded questionnaire on the preassessment of avoidance of any drugs or natural products affecting platelet functions. Preliminary investigations of screening tests of coagulation are performed in 10/14 (71.4%), while in 4/14 (28.6%), the diagnostic work-up of IPFD and von Willebrand disease (VWD) is performed simultaneously. The work-up of IPFD includes peripheral blood smear in 10/14 (71.4%), platelet aggregometry in all, flow cytometry in 10/14 (71.4%) and Platelet Function Analysis (PFA) in 3/11 (28.6%). Molecular genetic diagnosis is available in 7/14 (50%) centres.

CONCLUSIONS: The considerable variability in the current practice illustrates the need for harmonization between the Northern European centres according to the international registers (i.e. EUHASS) and IPFD guidelines (ISTH, EHA).

OriginalsprogEngelsk
TidsskriftHaemophilia Online
ISSN1365-2516
DOI
StatusE-pub ahead of print - 5 maj 2022

Bibliografisk note

© 2022 The Authors. Haemophilia published by John Wiley & Sons Ltd.

ID: 77929658